Literature DB >> 12606952

Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.

Jeremy Clark1, Sandra Edwards, Andrew Feber, Penny Flohr, Megan John, Ian Giddings, Sue Crossland, Michael R Stratton, Richard Wooster, Colin Campbell, Colin S Cooper.   

Abstract

We demonstrate that comparative genomic hybridization (CGH) onto cDNA microarrays may be used to carry out genome-wide screens for regions of genetic loss, including homozygous (complete) deletions that may represent the possible location of tumour suppressor genes in human cancer. Screening of the prostate cancer cell lines LNCaP, PC3 and DU145 allowed the mapping of specific regions where genome copy number appeared altered and led to the identification of two novel regions of complete loss at 17q21.31 (500 kb spanning STAT3) and at 10q23.1 (50-350 kb spanning SFTPA2) in the PC3 cell line.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12606952     DOI： 10.1038/sj.onc.1206247

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  43 in total

Review 1.  The role of nuclear factor κB in the interferon response.

Authors:  Lawrence M Pfeffer
Journal:  J Interferon Cytokine Res       Date:  2011-06-01       Impact factor: 2.607

2.  High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression.

Authors:  Maija Wolf; Spyro Mousses; Sampsa Hautaniemi; Ritva Karhu; Pia Huusko; Minna Allinen; Abdel Elkahloun; Outi Monni; Yidong Chen; Anne Kallioniemi; Olli-P Kallioniemi
Journal:  Neoplasia       Date:  2004 May-Jun       Impact factor: 5.715

3.  The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study.

Authors:  J Chaudhary; M Schmidt
Journal:  Chromosome Res       Date:  2006-07-12       Impact factor: 5.239

4.  Cytogenetically balanced translocations are associated with focal copy number alterations.

Authors:  Spencer K Watson; Ronald J deLeeuw; Doug E Horsman; Jeremy A Squire; Wan L Lam
Journal:  Hum Genet       Date:  2006-10-19       Impact factor: 4.132

5.  Survey of differentially methylated promoters in prostate cancer cell lines.

Authors:  Yipeng Wang; Qiuju Yu; Ann H Cho; Gaelle Rondeau; John Welsh; Eileen Adamson; Dan Mercola; Michael McClelland
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

6.  A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells.

Authors:  Hui Xiao; Hemant Kumar Bid; David Jou; Xiaojuan Wu; Wenying Yu; Chenglong Li; Peter J Houghton; Jiayuh Lin
Journal:  J Biol Chem       Date:  2014-10-13       Impact factor: 5.157

7.  IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis.

Authors:  Chuan He Yang; Junming Yue; Meiyun Fan; Lawrence M Pfeffer
Journal:  Cancer Res       Date:  2010-09-02       Impact factor: 12.701

8.  Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer.

Authors:  Wennuan Liu; Chunmei Carol Xie; Yi Zhu; Tao Li; Jishan Sun; Yu Cheng; Charles M Ewing; Sue Dalrymple; Aubrey R Turner; Jielin Sun; John T Isaacs; Bao-Li Chang; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

Review 9.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  27-Hydroxycholesterol Impairs Plasma Membrane Lipid Raft Signaling as Evidenced by Inhibition of IL6-JAK-STAT3 Signaling in Prostate Cancer Cells.

Authors:  Shweta Dambal; Mahmoud Alfaqih; Sergio Sanders; Erick Maravilla; Adela Ramirez-Torres; Gloria C Galvan; Mariana Reis-Sobreiro; Mirja Rotinen; Lucy M Driver; Matthew S Behrove; Tijana Jovanovic Talisman; Junhee Yoon; Sungyong You; James Turkson; Jen-Tsan Chi; Michael R Freeman; Everardo Macias; Stephen J Freedland
Journal:  Mol Cancer Res       Date:  2020-02-04       Impact factor: 5.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.